Company Overview
Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company focused on developing off-the-shelf precision T cell therapies designed to treat infectious diseases, cancers, and other disorders. Within the broader Healthcare sector, the company specifically functions within the biotechnology industry, a field characterized by high research and development costs and long product development timelines. The company's current market capitalization stands at $17.67M, while its annual revenue is not available for the trailing twelve-month period, and it employs 18 individuals. These valuation and operational metrics indicate that Tevogen Bio Holdings Inc. is a micro-cap entity with limited revenue generation relative to its development-stage status, suggesting a business model that prioritizes asset creation over immediate profit generation. The small employee count of 18 further underscores the lean organizational structure typical of early-stage biotechnology firms that rely heavily on intellectual property and external partnerships rather than large-scale manufacturing operations.
Financial Health
The company reported a net income of $-31,416,888 over the trailing twelve months, while revenue and EBITDA figures for the same period are not available in the current data set. The substantial negative net income relative to the reported EBITDA of $-30,720,460 reveals a cost structure dominated by non-operating expenses or significant one-time charges, as the gap between EBITDA and net income typically indicates the impact of interest, taxes, and other non-recurring items. Free cash flow stands at $-754,284, which signifies a heavy reliance on external capital sources to fund ongoing operations and development activities, thereby limiting immediate financial flexibility for unexpected market shifts. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, indicating that the company has not yet achieved commercial scale where revenue can cover the direct costs of goods sold and operating expenses to generate a positive percentage return. On the balance sheet, the company holds $1.04M in cash against total debt of $7.53M, resulting in a debt-to-equity ratio that is not available due to the specific financial reporting constraints of the entity. This debt position exceeds available cash reserves, suggesting a leveraged balance sheet that requires careful management of cash flow to avoid liquidity stress. The current ratio is 0.32, which indicates that the company possesses only 32 cents in current assets for every dollar of current liabilities, pointing to potential short-term liquidity challenges. Return on equity is not available, while return on assets is a severe -439.7%, revealing that the company's assets are currently generating negative returns and eroding shareholder value.
Valuation Assessment
The trailing P/E ratio and forward P/E ratio are both not available, which implies that traditional earnings-based valuation multiples cannot be applied given the company's current lack of profitability and the absence of forward earnings estimates. The price-to-book ratio is -1.04, a negative figure that indicates the market is valuing the company's equity at less than the net asset value, a situation often seen in biotechnology firms with significant intangible assets or liabilities that are not fully captured on the balance sheet. Since revenue is not available, the price-to-sales ratio is not available, and the EV/EBITDA stands at -1.06, these alternative valuation metrics collectively suggest that the company is priced based on potential future value rather than current cash flows or sales performance. The stock has traded between a 52-week low of $4.18 and a 52-week high of $75.50, and without the current price explicitly stated in the provided facts, the precise percentage deviation from this range cannot be calculated, though the wide spread indicates high volatility. The beta is -0.75, a negative value that suggests the stock price moves inversely to the broader market trends, displaying a volatility profile that is distinct from the majority of equities which typically exhibit positive beta correlations.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both not available, preventing a direct comparison of whether earnings are growing faster or slower than revenue, though the negative return on assets suggests a contraction in value rather than organic expansion. The company does not pay dividends, as the dividend yield is not available and the payout ratio is 0.0%, meaning the company reinvests all available resources and any generated earnings back into its research and development pipeline rather than distributing income to shareholders. This reinvestment strategy is characteristic of clinical-stage companies that must prioritize funding their pipeline of precision T cell therapies over returning capital to investors. The overall growth and income profile is defined by a complete absence of current profitability and dividend generation, relying entirely on future clinical trial successes and regulatory approvals to transition into a revenue-generating phase.